Copyright Reports & Markets. All rights reserved.

Global Chronic Idiopathic Constipation (CIC) Drugs Market Insights, Forecast to 2025

Buy now

Table of Contents

    1 Study Coverage

    • 1.1 Chronic Idiopathic Constipation (CIC) Drugs Product
    • 1.2 Market Segments
    • 1.3 Key Manufacturers Covered
    • 1.4 Market by Type
      • 1.4.1 Global Chronic Idiopathic Constipation (CIC) Drugs Market Size Growth Rate by Product
      • 1.4.2 Lubiprostone
      • 1.4.3 Linaclotide
      • 1.4.4 Others
    • 1.5 Market by End User
      • 1.5.1 Global Chronic Idiopathic Constipation (CIC) Drugs Market Size Growth Rate by End User
      • 1.5.2 Hospitals & Clinics
      • 1.5.3 Ambulatory Surgical Centres
      • 1.5.4 Long Term Care Centres
      • 1.5.5 Others
    • 1.6 Study Objectives
    • 1.7 Years Considered

    2 Executive Summary

    • 2.1 Global Chronic Idiopathic Constipation (CIC) Drugs Market Size
      • 2.1.1 Global Chronic Idiopathic Constipation (CIC) Drugs Revenue 2014-2025
      • 2.1.2 Global Chronic Idiopathic Constipation (CIC) Drugs Sales 2014-2025
    • 2.2 Chronic Idiopathic Constipation (CIC) Drugs Growth Rate by Regions
      • 2.2.1 Global Chronic Idiopathic Constipation (CIC) Drugs Sales by Regions
      • 2.2.2 Global Chronic Idiopathic Constipation (CIC) Drugs Revenue by Regions

    3 Breakdown Data by Manufacturers

    • 3.1 Chronic Idiopathic Constipation (CIC) Drugs Sales by Manufacturers
      • 3.1.1 Chronic Idiopathic Constipation (CIC) Drugs Sales by Manufacturers
      • 3.1.2 Chronic Idiopathic Constipation (CIC) Drugs Sales Market Share by Manufacturers
      • 3.1.3 Global Chronic Idiopathic Constipation (CIC) Drugs Market Concentration Ratio (CR5 and HHI)
    • 3.2 Chronic Idiopathic Constipation (CIC) Drugs Revenue by Manufacturers
      • 3.2.1 Chronic Idiopathic Constipation (CIC) Drugs Revenue by Manufacturers (2014-2019)
      • 3.2.2 Chronic Idiopathic Constipation (CIC) Drugs Revenue Share by Manufacturers (2014-2019)
    • 3.3 Chronic Idiopathic Constipation (CIC) Drugs Price by Manufacturers
    • 3.4 Chronic Idiopathic Constipation (CIC) Drugs Manufacturing Base Distribution, Product Types
      • 3.4.1 Chronic Idiopathic Constipation (CIC) Drugs Manufacturers Manufacturing Base Distribution, Headquarters
      • 3.4.2 Manufacturers Chronic Idiopathic Constipation (CIC) Drugs Product Type
      • 3.4.3 Date of International Manufacturers Enter into Chronic Idiopathic Constipation (CIC) Drugs Market
    • 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

    4 Breakdown Data by Product

    • 4.1 Global Chronic Idiopathic Constipation (CIC) Drugs Sales by Product
    • 4.2 Global Chronic Idiopathic Constipation (CIC) Drugs Revenue by Product
    • 4.3 Chronic Idiopathic Constipation (CIC) Drugs Price by Product

    5 Breakdown Data by End User

    • 5.1 Overview
    • 5.2 Global Chronic Idiopathic Constipation (CIC) Drugs Breakdown Data by End User

    6 North America

    • 6.1 North America Chronic Idiopathic Constipation (CIC) Drugs by Countries
      • 6.1.1 North America Chronic Idiopathic Constipation (CIC) Drugs Sales by Countries
      • 6.1.2 North America Chronic Idiopathic Constipation (CIC) Drugs Revenue by Countries
      • 6.1.3 United States
      • 6.1.4 Canada
      • 6.1.5 Mexico
    • 6.2 North America Chronic Idiopathic Constipation (CIC) Drugs by Product
    • 6.3 North America Chronic Idiopathic Constipation (CIC) Drugs by End User

    7 Europe

    • 7.1 Europe Chronic Idiopathic Constipation (CIC) Drugs by Countries
      • 7.1.1 Europe Chronic Idiopathic Constipation (CIC) Drugs Sales by Countries
      • 7.1.2 Europe Chronic Idiopathic Constipation (CIC) Drugs Revenue by Countries
      • 7.1.3 Germany
      • 7.1.4 France
      • 7.1.5 UK
      • 7.1.6 Italy
      • 7.1.7 Russia
    • 7.2 Europe Chronic Idiopathic Constipation (CIC) Drugs by Product
    • 7.3 Europe Chronic Idiopathic Constipation (CIC) Drugs by End User

    8 Asia Pacific

    • 8.1 Asia Pacific Chronic Idiopathic Constipation (CIC) Drugs by Countries
      • 8.1.1 Asia Pacific Chronic Idiopathic Constipation (CIC) Drugs Sales by Countries
      • 8.1.2 Asia Pacific Chronic Idiopathic Constipation (CIC) Drugs Revenue by Countries
      • 8.1.3 China
      • 8.1.4 Japan
      • 8.1.5 Korea
      • 8.1.6 India
      • 8.1.7 Australia
      • 8.1.8 Indonesia
      • 8.1.9 Malaysia
      • 8.1.10 Philippines
      • 8.1.11 Thailand
      • 8.1.12 Vietnam
      • 8.1.13 Singapore
    • 8.2 Asia Pacific Chronic Idiopathic Constipation (CIC) Drugs by Product
    • 8.3 Asia Pacific Chronic Idiopathic Constipation (CIC) Drugs by End User

    9 Central & South America

    • 9.1 Central & South America Chronic Idiopathic Constipation (CIC) Drugs by Countries
      • 9.1.1 Central & South America Chronic Idiopathic Constipation (CIC) Drugs Sales by Countries
      • 9.1.2 Central & South America Chronic Idiopathic Constipation (CIC) Drugs Revenue by Countries
      • 9.1.3 Brazil
    • 9.2 Central & South America Chronic Idiopathic Constipation (CIC) Drugs by Product
    • 9.3 Central & South America Chronic Idiopathic Constipation (CIC) Drugs by End User

    10 Middle East and Africa

    • 10.1 Middle East and Africa Chronic Idiopathic Constipation (CIC) Drugs by Countries
      • 10.1.1 Middle East and Africa Chronic Idiopathic Constipation (CIC) Drugs Sales by Countries
      • 10.1.2 Middle East and Africa Chronic Idiopathic Constipation (CIC) Drugs Revenue by Countries
      • 10.1.3 GCC Countries
      • 10.1.4 Turkey
      • 10.1.5 Egypt
      • 10.1.6 South Africa
    • 10.2 Middle East and Africa Chronic Idiopathic Constipation (CIC) Drugs by Product
    • 10.3 Middle East and Africa Chronic Idiopathic Constipation (CIC) Drugs by End User

    11 Company Profiles

    • 11.1 Actavis
      • 11.1.1 Actavis Company Details
      • 11.1.2 Company Business Overview
      • 11.1.3 Actavis Chronic Idiopathic Constipation (CIC) Drugs Sales, Revenue and Gross Margin (2014-2019)
      • 11.1.4 Actavis Chronic Idiopathic Constipation (CIC) Drugs Products Offered
      • 11.1.5 Actavis Recent Development
    • 11.2 Chugai Pharmaceutical
      • 11.2.1 Chugai Pharmaceutical Company Details
      • 11.2.2 Company Business Overview
      • 11.2.3 Chugai Pharmaceutical Chronic Idiopathic Constipation (CIC) Drugs Sales, Revenue and Gross Margin (2014-2019)
      • 11.2.4 Chugai Pharmaceutical Chronic Idiopathic Constipation (CIC) Drugs Products Offered
      • 11.2.5 Chugai Pharmaceutical Recent Development
    • 11.3 Ferring International Center
      • 11.3.1 Ferring International Center Company Details
      • 11.3.2 Company Business Overview
      • 11.3.3 Ferring International Center Chronic Idiopathic Constipation (CIC) Drugs Sales, Revenue and Gross Margin (2014-2019)
      • 11.3.4 Ferring International Center Chronic Idiopathic Constipation (CIC) Drugs Products Offered
      • 11.3.5 Ferring International Center Recent Development
    • 11.4 Synergy Pharmaceuticals
      • 11.4.1 Synergy Pharmaceuticals Company Details
      • 11.4.2 Company Business Overview
      • 11.4.3 Synergy Pharmaceuticals Chronic Idiopathic Constipation (CIC) Drugs Sales, Revenue and Gross Margin (2014-2019)
      • 11.4.4 Synergy Pharmaceuticals Chronic Idiopathic Constipation (CIC) Drugs Products Offered
      • 11.4.5 Synergy Pharmaceuticals Recent Development
    • 11.5 Pfizer
      • 11.5.1 Pfizer Company Details
      • 11.5.2 Company Business Overview
      • 11.5.3 Pfizer Chronic Idiopathic Constipation (CIC) Drugs Sales, Revenue and Gross Margin (2014-2019)
      • 11.5.4 Pfizer Chronic Idiopathic Constipation (CIC) Drugs Products Offered
      • 11.5.5 Pfizer Recent Development
    • 11.6 GlaxoSmithKline
      • 11.6.1 GlaxoSmithKline Company Details
      • 11.6.2 Company Business Overview
      • 11.6.3 GlaxoSmithKline Chronic Idiopathic Constipation (CIC) Drugs Sales, Revenue and Gross Margin (2014-2019)
      • 11.6.4 GlaxoSmithKline Chronic Idiopathic Constipation (CIC) Drugs Products Offered
      • 11.6.5 GlaxoSmithKline Recent Development
    • 11.7 Roche Holding
      • 11.7.1 Roche Holding Company Details
      • 11.7.2 Company Business Overview
      • 11.7.3 Roche Holding Chronic Idiopathic Constipation (CIC) Drugs Sales, Revenue and Gross Margin (2014-2019)
      • 11.7.4 Roche Holding Chronic Idiopathic Constipation (CIC) Drugs Products Offered
      • 11.7.5 Roche Holding Recent Development
    • 11.8 Sanofi
      • 11.8.1 Sanofi Company Details
      • 11.8.2 Company Business Overview
      • 11.8.3 Sanofi Chronic Idiopathic Constipation (CIC) Drugs Sales, Revenue and Gross Margin (2014-2019)
      • 11.8.4 Sanofi Chronic Idiopathic Constipation (CIC) Drugs Products Offered
      • 11.8.5 Sanofi Recent Development
    • 11.9 Bayer
      • 11.9.1 Bayer Company Details
      • 11.9.2 Company Business Overview
      • 11.9.3 Bayer Chronic Idiopathic Constipation (CIC) Drugs Sales, Revenue and Gross Margin (2014-2019)
      • 11.9.4 Bayer Chronic Idiopathic Constipation (CIC) Drugs Products Offered
      • 11.9.5 Bayer Recent Development
    • 11.10 Salix Pharmaceuticals
      • 11.10.1 Salix Pharmaceuticals Company Details
      • 11.10.2 Company Business Overview
      • 11.10.3 Salix Pharmaceuticals Chronic Idiopathic Constipation (CIC) Drugs Sales, Revenue and Gross Margin (2014-2019)
      • 11.10.4 Salix Pharmaceuticals Chronic Idiopathic Constipation (CIC) Drugs Products Offered
      • 11.10.5 Salix Pharmaceuticals Recent Development
    • 11.11 Sucampo Pharmaceuticals
    • 11.12 Ironwood Pharmaceuticals
    • 11.13 Progenics Pharmaceuticals

    12 Future Forecast

    • 12.1 Chronic Idiopathic Constipation (CIC) Drugs Market Forecast by Regions
      • 12.1.1 Global Chronic Idiopathic Constipation (CIC) Drugs Sales Forecast by Regions 2019-2025
      • 12.1.2 Global Chronic Idiopathic Constipation (CIC) Drugs Revenue Forecast by Regions 2019-2025
    • 12.2 Chronic Idiopathic Constipation (CIC) Drugs Market Forecast by Product
      • 12.2.1 Global Chronic Idiopathic Constipation (CIC) Drugs Sales Forecast by Product 2019-2025
      • 12.2.2 Global Chronic Idiopathic Constipation (CIC) Drugs Revenue Forecast by Product 2019-2025
    • 12.3 Chronic Idiopathic Constipation (CIC) Drugs Market Forecast by End User
    • 12.4 North America Chronic Idiopathic Constipation (CIC) Drugs Forecast
    • 12.5 Europe Chronic Idiopathic Constipation (CIC) Drugs Forecast
    • 12.6 Asia Pacific Chronic Idiopathic Constipation (CIC) Drugs Forecast
    • 12.7 Central & South America Chronic Idiopathic Constipation (CIC) Drugs Forecast
    • 12.8 Middle East and Africa Chronic Idiopathic Constipation (CIC) Drugs Forecast

    13 Market Opportunities, Challenges, Risks and Influences Factors Analysis

    • 13.1 Market Opportunities and Drivers
    • 13.2 Market Challenges
    • 13.3 Market Risks/Restraints
    • 13.4 Macroscopic Indicators

    14 Value Chain and Sales Channels Analysis

    • 14.1 Value Chain Analysis
    • 14.2 Chronic Idiopathic Constipation (CIC) Drugs Customers
    • 14.3 Sales Channels Analysis
      • 14.3.1 Sales Channels
      • 14.3.2 Distributors

    15 Research Findings and Conclusion

      16 Appendix

      • 16.1 Research Methodology
        • 16.1.1 Methodology/Research Approach
        • 16.1.2 Data Source
      • 16.2 Author Details

      Chronic idiopathic constipation (CIC) is a health condition in which a person experiences chronic symptoms of constipation, yet no visible cause can be identified through standard diagnostic testing. The term idiopathic is used because it means there is no known cause. CIC includes symptoms of difficult, infrequent, or incomplete bowel movements.
      The global Chronic Idiopathic Constipation (CIC) Drugs market is valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025. The objectives of this study are to define, segment, and project the size of the Chronic Idiopathic Constipation (CIC) Drugs market based on company, product type, end user and key regions.

      This report studies the global market size of Chronic Idiopathic Constipation (CIC) Drugs in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Chronic Idiopathic Constipation (CIC) Drugs in these regions.
      This research report categorizes the global Chronic Idiopathic Constipation (CIC) Drugs market by top players/brands, region, type and end user. This report also studies the global Chronic Idiopathic Constipation (CIC) Drugs market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.

      The following manufacturers are covered in this report, with sales, revenue, market share for each company:
      Actavis
      Chugai Pharmaceutical
      Ferring International Center
      Synergy Pharmaceuticals
      Pfizer
      GlaxoSmithKline
      Roche Holding
      Sanofi
      Bayer
      Salix Pharmaceuticals
      Sucampo Pharmaceuticals
      Ironwood Pharmaceuticals
      Progenics Pharmaceuticals

      Market size by Product
      Lubiprostone
      Linaclotide
      Others
      Market size by End User
      Hospitals & Clinics
      Ambulatory Surgical Centres
      Long Term Care Centres
      Others

      Market size by Region
      North America
      United States
      Canada
      Mexico
      Asia-Pacific
      China
      India
      Japan
      South Korea
      Australia
      Indonesia
      Singapore
      Malaysia
      Philippines
      Thailand
      Vietnam
      Europe
      Germany
      France
      UK
      Italy
      Spain
      Russia
      Central & South America
      Brazil
      Rest of Central & South America
      Middle East & Africa
      GCC Countries
      Turkey
      Egypt
      South Africa

      The study objectives of this report are:
      To study and analyze the global Chronic Idiopathic Constipation (CIC) Drugs market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
      To understand the structure of Chronic Idiopathic Constipation (CIC) Drugs market by identifying its various subsegments.
      To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
      Focuses on the key global Chronic Idiopathic Constipation (CIC) Drugs companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
      To project the value and sales volume of Chronic Idiopathic Constipation (CIC) Drugs submarkets, with respect to key regions.
      To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

      In this study, the years considered to estimate the market size of Chronic Idiopathic Constipation (CIC) Drugs are as follows:
      History Year: 2014-2018
      Base Year: 2018
      Estimated Year: 2019
      Forecast Year 2019 to 2025

      This report includes the estimation of market size for value (million US$) and volume (K Units). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Chronic Idiopathic Constipation (CIC) Drugs market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.

      For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

      Buy now